News from Bayer
May 10, 2022
First quarter at Bayer:
Very good start to the year – strong sales and earnings growth
May 03, 2022
Not intended for U.S. and UK Media
U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)
April 29, 2022
CEO Werner Baumann at the Annual Stockholders’ Meeting:
“Bayer is on the right track”